false
0000906709
0000906709
2024-05-09
2024-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
May 9, 2024
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
0-24006 |
|
94-3134940 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices and
Zip Code)
Registrant’s telephone number, including
area code: (415) 482-5300
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value |
|
NKTR |
|
Nasdaq Capital Market |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition.
On
May 9, 2024, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”)
announcing its financial results for the quarter ended March 31, 2024. A copy of the Press Release is furnished herewith as
Exhibit 99.1.
The
information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information
contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange
Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NEKTAR THERAPEUTICS |
|
|
|
Date: May 9, 2024 |
By: |
/s/ Mark A. Wilson |
|
|
Mark A. Wilson |
|
|
Chief Legal Officer and Secretary |
2
Exhibit
99.1
Nektar
Therapeutics Reports First Quarter 2024 Financial Results
SAN
FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended
March 31, 2024.
Cash
and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023. Nektar’s
cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026.
“In
the first quarter, we made significant progress with our highly promising immunology and inflammation pipeline,” said Howard W.
Robin, President and CEO of Nektar. “REZPEG is advancing in the clinic in our Phase 2b study in patients with atopic dermatitis
and in our Phase 2b study in patients with alopecia areata. Enrollment for both studies is on-track, and we expect to report topline
data from these trials in the first half of 2025. Building out our Treg pipeline, our novel bivalent antibody targeting the TNFR2 receptor
is progressing through IND-enabling studies to support entering the clinic next year.”
Summary
of Financial Results
Revenue
in the first quarter of 2024 was $21.6 million as compared to the same $21.6 million in the first quarter of 2023.
Total
operating costs and expenses in the first quarter of 2024 were $57.1 million as compared to $156.3 million in the first quarter of 2023.
Operating costs and expenses for the first quarter of 2023 included a one-time $76.5 million non-cash goodwill impairment charge. Operating
costs and expenses for the first quarter of 2024 further decreased as compared to 2023 due to decreases in restructuring, impairment
and costs of terminated program, as well as decreases in R&D and G&A expense.
R&D
expense in the first quarter of 2024 was $27.4 million as compared to $30.5 million for the first quarter of 2023. R&D expense for
the first quarter of 2024 decreased primarily due to a decrease in employee costs and related facilities costs, partially offset by an
increase in expense for the development of rezpegaldesleukin and NKTR-0165, our TNFR2 agonist antibody.
G&A
expense was $20.1 million in the first quarter of 2024 as compared to $21.1 million in the first quarter of 2023.
Restructuring,
impairment and other costs of the terminated program were $1.0 million in the first quarter of 2024 as compared to $21.2 million in the
first quarter of 2023. Restructuring, impairment and other costs of terminated program decreased primarily due to $13.2 million in non-cash
lease and equipment impairment charges and $5.5 million in severance expense recognized in the first quarter of 2023.
Net
loss for the first quarter of 2024 was $36.8 million or $0.19 basic and diluted loss per share as compared to a net loss of $137.0 million
or $0.73 basic and diluted loss per share in the first quarter of 2023.
First
Quarter 2024 and Recent Business Highlights
| ● | In
March 2024, Nektar initiated a Phase 2b study of rezpegaldesleukin in patients with severe-to-very
severe alopecia areata. The Company expects topline data from this study in the first half
of 2025. |
| ● | Enrollment
is ongoing in the Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe
atopic dermatitis. The Company expects topline data from this study in the first half of
2025. |
| ● | In March
2024, we entered into a securities purchase agreement with TCG Crossover Fund, an institutional
accredited investor, to sell securities in a private placement financing for gross proceeds
to the Company of approximately $30 million, before deducting expenses. |
Conference
Call to Discuss First Quarter 2024 Financial Results
Nektar
management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, May 9, 2024.
This
press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors
section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June
9, 2024.
To
access the conference call, follow these instructions:
Dial:
(800) 715-9871 (U.S & Canada)
Conference
ID: 4855448
About
Nektar Therapeutics
Nektar
Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction
in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a
novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one
in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor
type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist
designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered
in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Cautionary
Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements which can be identified by words such as: “will,” “expect,” “develop,”
“potential,” “advance,” “anticipate,” and similar references to future periods. Examples of forward-looking
statements include, among others, statements regarding the therapeutic potential of, and future development plans for, rezpegaldesleukin
and NKTR-0165. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based
only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated
events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.
Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated
in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin
and NKTR-0165 are based on preclinical and clinical findings and observations and are subject to change as research and development continue;
(ii) rezpegaldesleukin and NKTR-0165 are investigational agents and continued research and development for these drug candidates is subject
to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in
earlier preclinical and clinical studies); (iii) rezpegaldesleukin is in clinical development and NTKR-0165 is in preclinical development,
and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement
or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to challenges caused by health epidemics,
including the recent COVID-19 pandemic, regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing
standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure
in ultimately obtaining regulatory approval in one or more important markets; (v) we may not achieve the expected cost savings we expect
from our 2022 corporate restructuring and reorganization plan or our 2023 cost restructuring plan and we may undertake additional restructuring
and cost-saving activities in the future, (vi) patents may not issue from our patent applications for our drug candidates, patents that
have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain
other important risks and uncertainties set forth in our Quarterly Report on Form 10-K filed with the Securities and Exchange Commission
on March 5, 2024. Any forward-looking statement made by us in this press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written
or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
For
Investors:
Vivian
Wu of Nektar Therapeutics
628-895-0661
For
Media:
David
Rosen of Argot Partners
(212)
600-1902
david.rosen@argotpartners.com
NEKTAR
THERAPEUTICS
CONDENSED
CONSOLIDATED BALANCE SHEETS
(In
thousands)
(Unaudited)
| |
March 31,
2024 | | |
December 31,
2023(1) | |
ASSETS | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 48,642 | | |
$ | 35,277 | |
Short-term investments | |
| 240,596 | | |
| 268,339 | |
Accounts receivable | |
| 3,617 | | |
| 1,205 | |
Inventory, net | |
| 16,238 | | |
| 16,101 | |
Other current assets | |
| 10,743 | | |
| 9,779 | |
Total current assets | |
| 319,836 | | |
| 330,701 | |
| |
| | | |
| | |
Long-term investments | |
| 36,778 | | |
| 25,825 | |
Property, plant and equipment, net | |
| 17,475 | | |
| 18,856 | |
Operating lease right-of-use assets | |
| 17,267 | | |
| 18,007 | |
Other assets | |
| 4,656 | | |
| 4,644 | |
Total assets | |
$ | 396,012 | | |
$ | 398,033 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
| 8,757 | | |
| 9,848 | |
Accrued expenses | |
| 24,281 | | |
| 22,162 | |
Operating lease liabilities, current portion | |
| 19,368 | | |
| 19,259 | |
Total current liabilities | |
| 52,406 | | |
| 51,269 | |
| |
| | | |
| | |
Operating lease liabilities, less current portion | |
| 94,710 | | |
| 98,517 | |
Liabilities related to the sales of future royalties, net | |
| 117,857 | | |
| 112,625 | |
Other long-term liabilities | |
| 4,334 | | |
| 4,635 | |
Total liabilities | |
| 269,307 | | |
| 267,046 | |
| |
| | | |
| | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Preferred stock | |
| - | | |
| - | |
Common stock | |
| 19 | | |
| 19 | |
Capital in excess of par value | |
| 3,644,140 | | |
| 3,608,137 | |
Treasury stock | |
| (3,000 | ) | |
| - | |
Accumulated other comprehensive income (loss) | |
| (403 | ) | |
| 80 | |
Accumulated deficit | |
| (3,514,051 | ) | |
| (3,477,249 | ) |
Total stockholders’ equity | |
| 126,705 | | |
| 130,987 | |
Total liabilities and stockholders’ equity | |
$ | 396,012 | | |
$ | 398,033 | |
(1) | The consolidated balance sheet at December 31, 2023 has been
derived from the audited financial statements at that date but does not include all of the information and notes required by generally
accepted accounting principles in the United States for complete financial statements. |
NEKTAR
THERAPEUTICS
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(In
thousands, except per share information)
(Unaudited)
| |
Three months ended
March 31, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
Revenue: | |
| | |
| |
Product sales | |
$ | 6,034 | | |
$ | 4,718 | |
Non-cash royalty revenue related to the sales of future royalties | |
| 15,508 | | |
| 16,861 | |
License, collaboration and other revenue | |
| 97 | | |
| 15 | |
Total revenue | |
| 21,639 | | |
| 21,594 | |
| |
| | | |
| | |
Operating costs and expenses: | |
| | | |
| | |
Cost of goods sold | |
| 8,534 | | |
| 7,060 | |
Research and development | |
| 27,408 | | |
| 30,469 | |
General and administrative | |
| 20,149 | | |
| 21,081 | |
Restructuring, impairment and costs of terminated program | |
| 975 | | |
| 21,193 | |
Impairment of goodwill | |
| - | | |
| 76,501 | |
Total operating costs and expenses | |
| 57,066 | | |
| 156,304 | |
| |
| | | |
| | |
Loss from operations | |
| (35,427 | ) | |
| (134,710 | ) |
| |
| | | |
| | |
Non-operating income (expense): | |
| | | |
| | |
Non-cash interest expense on liabilities related to the sales of future royalties | |
| (5,531 | ) | |
| (6,405 | ) |
Interest income | |
| 4,220 | | |
| 4,335 | |
Other income (expense), net | |
| (99 | ) | |
| (301 | ) |
Total non-operating income (expense), net | |
| (1,410 | ) | |
| (2,371 | ) |
| |
| | | |
| | |
Loss before provision for income taxes | |
| (36,837 | ) | |
| (137,081 | ) |
| |
| | | |
| | |
Provision (benefit) for income taxes | |
| (35 | ) | |
| (63 | ) |
Net loss | |
$ | (36,802 | ) | |
$ | (137,018 | ) |
| |
| | | |
| | |
Basic and diluted net loss per share | |
$ | (0.19 | ) | |
$ | (0.73 | ) |
| |
| | | |
| | |
Weighted average shares outstanding used in computing basic and diluted net loss per share | |
| 194,746 | | |
| 188,875 | |
5
v3.24.1.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Nektar Therapeutics (NASDAQ:NKTR)
過去 株価チャート
から 5 2024 まで 6 2024
Nektar Therapeutics (NASDAQ:NKTR)
過去 株価チャート
から 6 2023 まで 6 2024